Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection

ACS Infect Dis. 2021 May 14;7(5):1059-1068. doi: 10.1021/acsinfecdis.0c00432. Epub 2020 Oct 29.

Abstract

Gut microbiota dysbiosis has been linked to many heath disorders including hepatitis C virus (HCV) infection. However, profiles of the gut microbiota alterations in HCV are inconsistent in the literature and are affected by the treatment regimens. Using samples collected prior to treatment from newly diagnosed patients, we characterized the gut microbiota structure in HCV patients as compared to healthy controls. Treatment-naive HCV microbiota showed increased diversity, an increased abundance of Prevotella, Succinivibrio, Catenibacterium, Megasphaera, and Ruminococcaceae, and a lower abundance of Bacteroides, Dialister, Bilophila, Streptococcus, parabacteroides, Enterobacteriaceae, Erysipelotrichaceae, Rikenellaceae, and Alistipes. Predicted community metagenomic functions showed a depletion of carbohydrate and lipid metabolism in HCV microbiota along with perturbations of amino acid metabolism. Receiver-operating characteristic analysis identified five disease-specific operational taxonomic units (OTUs) as potential biomarkers of HCV infections. Collectively, our findings reveal the alteration of gut microbiota in treatment naive HCV patients and suggest that gut microbiota may hold diagnostic promise in HCV infection.

Keywords: gut dysbiosis; gut microbiome; gut-liver axis; hepatitis C; microbial biomarkers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dysbiosis
  • Gastrointestinal Microbiome*
  • Hepacivirus / genetics
  • Hepatitis C* / diagnosis
  • Humans
  • Metagenomics